about
Therapy for Parkinson's disease: what is in the pipeline?Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseModeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's diseaseIntrastriatal transplantation of retinal pigment epithelial cells for the treatment of Parkinson disease: in vivo longitudinal molecular imaging with 18F-P3BZA PET/CTNOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation AnalysisComplexity of dopamine metabolism.Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.Management of motor and non-motor symptoms in Parkinson's disease.Animal models of Parkinson's disease: a gateway to therapeutics?Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.New and emerging medical therapies in Parkinson's disease.The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain.Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.Pulling habits out of rats: adenosine 2A receptor antagonism in dorsomedial striatum rescues meth-amphetamine-induced deficits in goal-directed action.
P2860
Q26991826-C2F0128A-6F56-4A08-9F80-829C47F6771EQ27301283-87F5785F-1F90-4846-9122-09D9D74AA6C7Q33924432-8476FD6A-7811-448B-8F22-9041EF23DDDDQ34688815-6BBD3E5D-B59B-46D4-A48D-6A0C652775C5Q35985407-BC50493B-C3F4-46E1-B0AC-DDE7553F6718Q36885946-DE510208-5AF6-4B50-83AA-002E3EB2D7DEQ36958208-B3AAAF9B-C72A-45FD-933B-6BF505599EB0Q37193201-C0EDA4B6-4032-42EB-9537-D59AA5BDEC95Q37209730-8FACCF8F-961C-4878-A079-B01FD3835FE4Q37708588-2C935A7B-2D4C-4387-92FF-4123A51AE8B5Q38091653-B223E44E-F5B7-4C0B-A011-8EDAC8B9D042Q38155480-BE3C4E3C-E31D-4A1B-A7A4-5034573F56C0Q38179453-E1E8E989-DC00-4264-A047-D5787A08F2F1Q38718194-AC588914-E2EA-49A2-87E3-9E35FE14994BQ39136811-932A5F12-1F9F-4849-A2EC-3A04E3150D84Q42244482-41932D92-D6E9-4949-8FA6-825FAC68281EQ42676936-701BEA55-3DF4-429D-9A46-19EAD52687FCQ43248920-F7B2BD05-9541-4DD5-98C4-B1D3F96B4446Q47646226-AAFE0EFA-984B-40DA-9925-35D98CBC2FBB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging therapies for Parkinson's disease.
@en
type
label
Emerging therapies for Parkinson's disease.
@en
prefLabel
Emerging therapies for Parkinson's disease.
@en
P50
P1476
Emerging therapies for Parkinson's disease.
@en
P304
P356
10.1097/WCO.0B013E3283542FDE
P577
2012-08-01T00:00:00Z